• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三元 Eg5-ADP-艾司匹替尼复合物的结构。

The structure of the ternary Eg5-ADP-ispinesib complex.

作者信息

Talapatra S K, Schüttelkopf A W, Kozielski F

机构信息

Molecular Motor Laboratory, The Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, Scotland, UK.

出版信息

Acta Crystallogr D Biol Crystallogr. 2012 Oct;68(Pt 10):1311-9. doi: 10.1107/S0907444912027965. Epub 2012 Sep 13.

DOI:10.1107/S0907444912027965
PMID:22993085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3447400/
Abstract

The human kinesin Eg5 is responsible for bipolar spindle formation during early mitosis. Inhibition of Eg5 triggers the formation of monoastral spindles, leading to mitotic arrest that eventually causes apoptosis. There is increasing evidence that Eg5 constitutes a potential drug target for the development of cancer chemotherapeutics. The most advanced Eg5-targeting agent is ispinesib, which exhibits potent antitumour activity and is currently in multiple phase II clinical trials. In this study, the crystal structure of the Eg5 motor domain in complex with ispinesib, supported by kinetic and thermodynamic binding data, is reported. Ispinesib occupies the same induced-fit pocket in Eg5 as other allosteric inhibitors, making extensive hydrophobic interactions with the protein. The data for the Eg5-ADP-ispinesib complex suffered from pseudo-merohedral twinning and revealed translational noncrystallographic symmetry, leading to challenges in data processing, space-group assignment and structure solution as well as in refinement. These complications may explain the lack of available structural information for this important agent and its analogues. The present structure represents the best interpretation of these data based on extensive data-reduction, structure-solution and refinement trials.

摘要

人类驱动蛋白Eg5在有丝分裂早期负责双极纺锤体的形成。抑制Eg5会触发单星体纺锤体的形成,导致有丝分裂停滞,最终引发细胞凋亡。越来越多的证据表明,Eg5构成了开发癌症化疗药物的潜在靶点。最先进的Eg5靶向剂是艾司匹西布,它具有强大的抗肿瘤活性,目前正处于多项II期临床试验中。在本研究中,报告了与艾司匹西布复合的Eg5运动结构域的晶体结构,并得到了动力学和热力学结合数据的支持。艾司匹西布与其他变构抑制剂一样,占据Eg5中相同的诱导契合口袋,与蛋白质形成广泛的疏水相互作用。Eg5-ADP-艾司匹西布复合物的数据存在假单形孪晶,并显示出平移非晶体学对称性,这给数据处理、空间群归属、结构解析以及精修带来了挑战。这些复杂情况可能解释了关于这种重要药物及其类似物缺乏可用结构信息的原因。目前的结构是基于广泛的数据简化、结构解析和精修试验对这些数据的最佳解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/3ce1d12ed24e/d-68-01311-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/c326e6a8780d/d-68-01311-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/beb790732823/d-68-01311-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/75e70c040531/d-68-01311-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/3ce1d12ed24e/d-68-01311-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/c326e6a8780d/d-68-01311-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/beb790732823/d-68-01311-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/75e70c040531/d-68-01311-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b7e/3447400/3ce1d12ed24e/d-68-01311-fig4.jpg

相似文献

1
The structure of the ternary Eg5-ADP-ispinesib complex.三元 Eg5-ADP-艾司匹替尼复合物的结构。
Acta Crystallogr D Biol Crystallogr. 2012 Oct;68(Pt 10):1311-9. doi: 10.1107/S0907444912027965. Epub 2012 Sep 13.
2
"Snapshots" of ispinesib-induced conformational changes in the mitotic kinesin Eg5.伊匹尼司他诱导有丝分裂运动蛋白 Eg5 构象变化的“快照”。
J Biol Chem. 2013 Jun 21;288(25):18588-98. doi: 10.1074/jbc.M113.462648. Epub 2013 May 8.
3
Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.核苷酸与抑制剂结合至野生型和耐ispsinesib形式的人驱动蛋白纺锤体蛋白的热力学
Biochemistry. 2009 Nov 24;48(46):11045-55. doi: 10.1021/bi900946r.
4
The crystal structure and biochemical characterization of Kif15: a bifunctional molecular motor involved in bipolar spindle formation and neuronal development.驱动蛋白15(Kif15)的晶体结构与生化特性:一种参与双极纺锤体形成和神经元发育的双功能分子马达
Acta Crystallogr D Biol Crystallogr. 2014 Jan;70(Pt 1):123-33. doi: 10.1107/S1399004713028721. Epub 2013 Dec 24.
5
Mechanism of inhibition of human KSP by ispinesib.艾司西匹宁对人KSP的抑制机制。
Biochemistry. 2008 Mar 18;47(11):3576-85. doi: 10.1021/bi702061g. Epub 2008 Feb 22.
6
Binding patterns of inhibitors to different pockets of kinesin Eg5.抑制剂与驱动蛋白 Eg5 不同口袋的结合模式。
Arch Biochem Biophys. 2024 Jun;756:109998. doi: 10.1016/j.abb.2024.109998. Epub 2024 Apr 18.
7
Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.抑制剂文库筛选鉴定伊匹尼司他为一种新的胰腺癌潜在化疗药物。
Cancer Sci. 2021 Nov;112(11):4641-4654. doi: 10.1111/cas.15134. Epub 2021 Oct 2.
8
Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.ADP 释放速率的显著下降是二甲奈醌抑制有丝分裂驱动蛋白 Eg5 和癌细胞增殖的强大活性的基础。
Biochem Biophys Res Commun. 2014 May 9;447(3):465-70. doi: 10.1016/j.bbrc.2014.04.023. Epub 2014 Apr 13.
9
Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker.有丝分裂纺锤体驱动蛋白Eg5的晶体结构揭示了颈链的一种新构象。
J Biol Chem. 2001 Jul 6;276(27):25496-502. doi: 10.1074/jbc.M100395200. Epub 2001 Apr 27.
10
Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.在存在二磷酸腺苷(ADP)和三磷酸腺苷(ATP)的情况下,莫那可林与驱动蛋白样蛋白5(Eg5)变构相互作用的差异:傅里叶变换红外光谱(FT-IR)差异研究
Biochemistry. 2004 Aug 10;43(31):9939-49. doi: 10.1021/bi048982y.

引用本文的文献

1
Mitotic Functions and Characters of KIF11 in Cancers.癌症中KIF11的有丝分裂功能与特征
Biomolecules. 2024 Mar 22;14(4):386. doi: 10.3390/biom14040386.
2
Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC.依赖变构的耐药性:一种P环僵直Eg5突变体对STLC的变构抑制具有抗性。
Front Oncol. 2022 Oct 12;12:965455. doi: 10.3389/fonc.2022.965455. eCollection 2022.
3
MD simulation-based screening approach identified tolvaptan as a potential inhibitor of Eg5.基于 MD 模拟的筛选方法鉴定托伐普坦为 Eg5 的潜在抑制剂。

本文引用的文献

1
Elucidating the functionality of kinesins: an overview of small molecule inhibitors.阐明驱动蛋白的功能:小分子抑制剂概述。
Semin Cell Dev Biol. 2011 Dec;22(9):935-45. doi: 10.1016/j.semcdb.2011.09.023. Epub 2011 Oct 6.
2
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors.评估AZD4877在日本实体瘤患者中的安全性、耐受性和药代动力学的I期研究。
Arch Drug Inf. 2011 Jun;4(2):23-31. doi: 10.1111/j.1753-5174.2011.00034.x.
3
REFMAC5 for the refinement of macromolecular crystal structures.
Mol Divers. 2023 Jun;27(3):1203-1221. doi: 10.1007/s11030-022-10482-w. Epub 2022 Jul 4.
4
Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.抑制剂文库筛选鉴定伊匹尼司他为一种新的胰腺癌潜在化疗药物。
Cancer Sci. 2021 Nov;112(11):4641-4654. doi: 10.1111/cas.15134. Epub 2021 Oct 2.
5
Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands.基于异长春花碱衍生配体的 Ru、Os、Rh 和 Ir 半三明治配合物的金属依赖性细胞毒性和驱动蛋白纺锤体蛋白抑制活性。
Inorg Chem. 2020 Oct 19;59(20):14879-14890. doi: 10.1021/acs.inorgchem.0c00957. Epub 2020 Oct 1.
6
enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9.enAsCas12a 使 CRISPR 指导的进化能够筛选出 SpCas9 无法接近的序列中的功能性药物抗性突变。
Mol Ther. 2021 Jan 6;29(1):208-224. doi: 10.1016/j.ymthe.2020.09.025. Epub 2020 Sep 20.
7
Structural and Thermodynamic Basis of the Enhanced Interaction between Kinesin Spindle Protein Eg5 and STLC-type Inhibitors.驱动蛋白纺锤体蛋白Eg5与STLC型抑制剂之间增强相互作用的结构和热力学基础
ACS Omega. 2018 Sep 28;3(9):12284-12294. doi: 10.1021/acsomega.8b00778. eCollection 2018 Sep 30.
8
Predicting protein-ligand interactions based on bow-pharmacological space and Bayesian additive regression trees.基于 Bow 药效空间和贝叶斯加法回归树预测蛋白质-配体相互作用。
Sci Rep. 2019 May 22;9(1):7703. doi: 10.1038/s41598-019-43125-6.
9
Insights into the Molecular Mechanisms of Eg5 Inhibition by (+)-Morelloflavone.(+)-桑橙黄素抑制Eg5的分子机制研究
Pharmaceuticals (Basel). 2019 Apr 16;12(2):58. doi: 10.3390/ph12020058.
10
Cancer drug therapy and stochastic modeling of "nano-motors".癌症药物治疗与“纳米马达”的随机建模。
Int J Nanomedicine. 2018 Oct 15;13:6429-6440. doi: 10.2147/IJN.S168780. eCollection 2018.
用于大分子晶体结构精修的REFMAC5
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67. doi: 10.1107/S0907444911001314. Epub 2011 Mar 18.
4
Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.发现驱动蛋白纺锤体蛋白(KSP)的别构抑制剂用于治疗紫杉醇耐药性癌症:MK-0731 及其类似物。
Anticancer Agents Med Chem. 2010 Nov 1;10(9):697-712. doi: 10.2174/187152010794479807.
5
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.小儿科 I 期临床试验和伊匹尼司他的药代动力学研究:儿童肿瘤学组 I 期联盟研究。
Pediatr Blood Cancer. 2010 Dec 15;55(7):1323-8. doi: 10.1002/pbc.22609. Epub 2010 Aug 13.
6
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.一项在人体中首次研究 SB-743921 的研究,这是一种驱动蛋白纺锤体蛋白抑制剂,旨在确定药代动力学、生物学效应,并确定推荐的 II 期剂量。
Cancer Chemother Pharmacol. 2011 Feb;67(2):447-54. doi: 10.1007/s00280-010-1346-5. Epub 2010 May 12.
7
XDS.XDS.(这个词如果没有更多背景信息,很难准确翻译出更有意义的内容,直接保留原文是一种处理方式,或者音译为“克斯达斯”之类,但感觉都不太符合常规翻译场景,你可以补充更多关于这个词的信息以便我更准确翻译 )
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32. doi: 10.1107/S0907444909047337. Epub 2010 Jan 22.
8
How kinesin motor proteins drive mitotic spindle function: Lessons from molecular assays.驱动有丝分裂纺锤体功能的驱动蛋白马达蛋白:分子检测的启示。
Semin Cell Dev Biol. 2010 May;21(3):260-8. doi: 10.1016/j.semcdb.2010.01.018. Epub 2010 Jan 28.
9
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.一项伊匹尼司他(一种驱动蛋白纺锤体蛋白抑制剂)的 I 期研究,在实体瘤患者中,每 28 天周期的连续 3 周内每周给药,连续给药 3 周。
Invest New Drugs. 2011 Jun;29(3):467-72. doi: 10.1007/s10637-009-9374-x. Epub 2010 Jan 13.
10
MolProbity: all-atom structure validation for macromolecular crystallography.MolProbity:用于大分子晶体学的全原子结构验证
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. doi: 10.1107/S0907444909042073. Epub 2009 Dec 21.